FCM
TMO icon

Farallon Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Farallon Capital Management’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$433M Buy
881,485
+245,800
+39% +$133M 2.47% 15
2025
Q4 		$368M Sell
635,685
-622,556
-49% -$352M 1.67% 20
2025
Q3 		$610M Sell
1,258,241
-125,000
-9% -$58.2M 2.5% 11
2025
Q2 		$561M Buy
1,383,241
+347,385
+34% +$145M 2.36% 12
2025
Q1 		$515M Sell
1,035,856
-197,400
-16% -$107M 2.47% 15
2024
Q4 		$642M Buy
1,233,256
+523,800
+74% +$288M 2.82% 10
2024
Q3 		$439M Sell
709,456
-29,700
-4% -$17.6M 1.93% 18
2024
Q2 		$409M Sell
739,156
-58,260
-7% -$33.4M 1.75% 18
2024
Q1 		$463M Sell
797,416
-405,715
-34% -$228M 1.97% 15
2023
Q4 		$639M Buy
1,203,131
+155,600
+15% +$75.3M 2.92% 5
2023
Q3 		$530M Sell
1,047,531
-196,128
-16% -$105M 2.47% 9
2023
Q2 		$649M Buy
1,243,659
+194,600
+19% +$105M 3.26% 5
2023
Q1 		$605M Sell
1,049,059
-112,900
-10% -$63.6M 3.3% 4
2022
Q4 		$640M Buy
1,161,959
+39,900
+4% +$21.1M 3.78% 3
2022
Q3 		$569M Sell
1,122,059
-120,400
-10% -$67.4M 3.13% 3
2022
Q2 		$675M Buy
1,242,459
+18,600
+2% +$10.2M 3.66% 3
2022
Q1 		$723M Buy
1,223,859
+250,900
+26% +$144M 3.49% 2
2021
Q4 		$649M Sell
972,959
-6,700
-0.7% -$4.18M 3.24% 7
2021
Q3 		$560M Sell
979,659
-364,419
-27% -$200M 2.61% 7
2021
Q2 		$678M Buy
1,344,078
+189,000
+16% +$89.2M 2.77% 6
2021
Q1 		$527M Buy
1,155,078
+40,830
+4% +$19.5M 2.62% 7
2020
Q4 		$519M Buy
1,114,248
+18,670
+2% +$8.75M 3.12% 4
2020
Q3 		$484M Buy
1,095,578
+26,073
+2% +$10.8M 3.35% 4
2020
Q2 		$388M Sell
1,069,505
-173,710
-14% -$58.2M 3.1% 6
2020
Q1 		$353M Buy
1,243,215
+390,055
+46% +$123M 3.03% 6
2019
Q4 		$277M Buy
+853,160
New +$259M 1.87% 17

Other funds holding TMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Farallon Capital Management's TMO Position: Q1 2026 in Review

Farallon Capital Management increased its Thermo Fisher Scientific (TMO) stake by 39% in Q1 2026, buying an estimated $133M and bringing the position to 881,485 shares worth $433M. The position accounts for 2.47% of the portfolio, ranked #15.

Farallon Capital Management first reported a position in TMO in Q4 2019 and has held it in 26 quarters since. The position peaked at $723M in Q1 2022. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Farallon Capital Management held 881,485 shares of Thermo Fisher Scientific worth $433M as of Q1 2026.
  • Farallon Capital Management bought 245,800 Thermo Fisher Scientific shares in Q1 2026, an estimated $133M.
  • Thermo Fisher Scientific made up 2.47% of Farallon Capital Management's portfolio in Q1 2026, its #15 holding.
  • Farallon Capital Management first reported a position in Thermo Fisher Scientific in Q4 2019 and has held it in 26 quarters since.
  • Farallon Capital Management's Thermo Fisher Scientific position peaked at $723M in Q1 2022.
  • 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.